2022
DOI: 10.3390/ijms23116125
|View full text |Cite
|
Sign up to set email alerts
|

New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents

Abstract: Carbonic anhydrase IX (CAIX) is a tumor-specific and hypoxia-induced biomarker for the molecular imaging of solid malignancies. The nuclear- and optical-imaging of CAIX-expressing tumors have received great attention due to their potential for clinical applications. Nuclear imaging is a powerful tool for the non-invasive diagnosis of primary and metastatic CAIX-positive tumors and for the assessment of responses to antineoplastic treatment. Intraoperative optical fluorescence imaging provides improved visualiz… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 73 publications
0
8
0
Order By: Relevance
“…By catalyzing the interconversion of CO 2 and HCO 3 − to maintain intracellular pH homeostasis, the overexpression of CAIX contributes to cancer cell survival. Not only does CAIX modulate the microenvironment, but it also has a critical role in mediating tumor survival, spreading, and metastasis [ 25 ]. Hence, CAIX has become an interesting target not only for cancer diagnosis but also for treatment.…”
Section: Monoclonal Antibodies (Mabs) Clinically Approved For the Tre...mentioning
confidence: 99%
“…By catalyzing the interconversion of CO 2 and HCO 3 − to maintain intracellular pH homeostasis, the overexpression of CAIX contributes to cancer cell survival. Not only does CAIX modulate the microenvironment, but it also has a critical role in mediating tumor survival, spreading, and metastasis [ 25 ]. Hence, CAIX has become an interesting target not only for cancer diagnosis but also for treatment.…”
Section: Monoclonal Antibodies (Mabs) Clinically Approved For the Tre...mentioning
confidence: 99%
“…A relevant number of papers dealing with this enzyme, its inhibitors, activators and involvement in various diseases have been published in 2022 in this journal [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. The first group of contributed materials dealt with the use of this protein for investigations of basic biochemical approaches, such as protein folding [ 7 ], thermodynamic parameters assessment for protein–ligand interactions [ 8 ], bioluminescence resonance energy transfer connected to the binding of the metal ion to apoenzymes [ 9 ], the possibility to evidence chalcogen bonds in the X-ray crystal structures of CA–lig and adduct [ 10 ].…”
Section: State Of the Artmentioning
confidence: 99%
“…A large number of CA-related papers dealt with the drug design of CA inhibitors (CAIs) with various applications as anticancer agents (both for treatment and imaging) [ 13 , 14 , 15 , 16 , 17 , 18 , 19 ], antineuropathic pain compounds [ 20 ], mountain sickness leads [ 21 ], antiglaucoma agents [ 22 ] or antibacterials with a novel mechanism of action which, unlike classical antibiotics, target bacterial CAs from various pathogens [ 23 , 24 , 25 ]. Both sulfonamide and non-sulfonamide compounds have been reported in these interesting papers, which highly enrich the number of such pharmacological agents useful for the management of a multitude of pathological conditions [ 2 , 3 ].…”
Section: State Of the Artmentioning
confidence: 99%
“…This interest stems from their unique characteristics, in which chemically identical entities can be used for diagnosis and cancer treatment by incorporating various radionuclides. The most suitable design approach, proven in the field of CAIX-targeting theranostic molecules, involves the formation of a conjugate between an effective CAIX inhibitor and a metal chelator, tethered with a suitable linker . The ideal radiotracer must have high sensitivity and high specificity for CAIX-positive metastases.…”
Section: Introductionmentioning
confidence: 99%